CLINICAL_TRIALS
trial_result
· 2011-05-05
Clinical Trial Update: Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) [Phase 2]
Summary
A Phase 2 trial evaluating subcutaneous belimumab in systemic lupus erythematosus was terminated, with results posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Human Genome Sciences Inc. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2011-05-05